US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Articles published by AB Science

< Previous 1 2 3 Next >
News headline image
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.
From AB Science
Via GlobeNewswire
News headline image
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
From AB Science
Via GlobeNewswire
News headline image
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
From AB Science
Via GlobeNewswire
News headline image
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
From AB Science
Via GlobeNewswire
News headline image
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
From AB Science
Via GlobeNewswire
News headline image
AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
From AB Science
Via GlobeNewswire
News headline image
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
From AB Science
Via GlobeNewswire
News headline image
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
From AB Science
Via GlobeNewswire
News headline image
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
From AB Science
Via GlobeNewswire
News headline image
AB Science reports its revenues for the year 2025 and provides an update on its activities
From AB Science
Via GlobeNewswire
News headline image
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
From AB Science
Via GlobeNewswire
News headline image
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
From AB Science
Via GlobeNewswire
News headline image
AB Science provides an update on its clinical development program.
From AB Science
Via GlobeNewswire
News headline image
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
From AB Science
Via GlobeNewswire
News headline image
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
From AB Science
Via GlobeNewswire
News headline image
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer
From AB Science
Via GlobeNewswire
News headline image
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
From AB Science
Via GlobeNewswire
News headline image
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
From AB Science
Via GlobeNewswire
News headline image
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
From AB Science
Via GlobeNewswire
News headline image
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
From AB Science
Via GlobeNewswire
News headline image
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
From AB Science
Via GlobeNewswire
News headline image
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
From AB Science
Via GlobeNewswire
News headline image
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
From AB Science
Via GlobeNewswire
News headline image
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
From AB Science
Via GlobeNewswire
News headline image
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
From AB Science
Via GlobeNewswire
News headline image
AB Science announces a slight delay in the publication of its 2025 half-year financial report
From AB Science
Via GlobeNewswire
News headline image
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
From AB Science
Via GlobeNewswire
News headline image
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
From AB Science
Via GlobeNewswire
News headline image
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
From AB Science
Via GlobeNewswire
News headline image
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
From AB Science
Via GlobeNewswire
< Previous 1 2 3 Next >